The Grete Lundbeck European Brain Research Foundation announced today that The Brain Prize 2012 is jointly awarded to Christine Petit and Karen Steel:
  Viaskin Peanut, the first epicutaneous skin patch for the treatment of peanut allergy, is recognized as a unique and promising desensitization product   BAGNEUX, France, February 28, 2012 – DBV Technologies announced today that it has received Fast Track Designation” for the Clinical Development Program of its Viaskin® Peanut, a product designed for the...
  LA JOLLA, Calif., Feb. 15, 2012 /PRNewswire/ — Celladon Corporation, a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, announced today that it has completed a $43 million equity financing to advance its lead investigational product candidate MYDICAR® for the treatment of heart failure. The financing was led...
The Lundbeck Foundation is expanding its activities and establishing start up financing for selected new Danish life science projects. We are seeking a partner with industrial and operational experience combined with solid academic background to be a partner in this program.
Light is life-giving. Emission of absorbed light, or fluorescence, has given life to young scientist's career. The Lundbeck Foundation has awarded the 30-year-old post.doc. Thomas Just Sørensen, Keble College, Oxford University and Department of Chemistry, University of Copenhagen the Talent Prize for younger scientists. The prize is a personal award of 100.000 DKK (approx. £11.000).
Veloxis Pharmaceuticals A/S (OMX: VELO) today announced dosing of the first patient in the STRATO (Switching kidney TRAnsplant patients with Tremor to LCP-tacrO) Phase IIIb study of LCP-TacroT in kidney transplant recipients experiencing drug-induced tremors. The STRATO study is designed to explore whether a conversion of patients who have symptomatic tremor from treatment with standard...
Acacia Pharma, a pharmaceutical company specialising in the development of drugs for cancer supportive care, announces the initiation of a Phase II study of APD421, in the prevention of post-operative nausea & vomiting (PONV). PONV remains a clinically significant problem in patients undergoing major surgery, despite the availability of a range of anti-emetic medications. APD421...
1 2 3 4 5


Experienced neuroscientist at the helm of The Brain Prize
30. June 2020
Eight promising young researchers receive Lundbeck Foundation Fellowships
16. June 2020
Denmark Gets Its First Master’s Degree Programme in Neuroscience
4. June 2020


Lundbeckfonden Ventures

Lundbeckfonden Emerge